201 related articles for article (PubMed ID: 17313422)
1. Botulinum toxin A in the overactive bladder: current status and future directions.
Dmochowski R; Sand PK
BJU Int; 2007 Feb; 99(2):247-62. PubMed ID: 17313422
[No Abstract] [Full Text] [Related]
2. Botulinum toxin a in the overactive bladder: current status and future directions.
Mallina R; Sahai A; Khan MS; Dasgupta P
BJU Int; 2007 Jun; 99(6):1549-50. PubMed ID: 17537223
[No Abstract] [Full Text] [Related]
3. Changing treatments for overactive bladder.
Waine E; Stott M
Nurs Times; 2008 Oct 14-20; 104(41):45-8. PubMed ID: 18979960
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin--new mechanisms, new therapeutic directions?
Chapple C; Patel A
Eur Urol; 2006 Apr; 49(4):606-8. PubMed ID: 16457945
[No Abstract] [Full Text] [Related]
5. Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: is incomplete bladder emptying predictable?
Sahai A; Sangster P; Kalsi V; Khan MS; Fowler CJ; Dasgupta P
BJU Int; 2009 Mar; 103(5):630-4. PubMed ID: 18990156
[TBL] [Abstract][Full Text] [Related]
6. Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux.
Karsenty G; Elzayat E; Delapparent T; St-Denis B; Lemieux MC; Corcos J
J Urol; 2007 Mar; 177(3):1011-4. PubMed ID: 17296399
[TBL] [Abstract][Full Text] [Related]
7. The use of botulinum toxin type A in urological procedures.
Lajiness MJ
Urol Nurs; 2009; 29(6):445-50. PubMed ID: 20088238
[TBL] [Abstract][Full Text] [Related]
8. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy.
Giannantoni A; Rossi A; Mearini E; Del Zingaro M; Porena M; Berardelli A
J Urol; 2009 Oct; 182(4):1453-7. PubMed ID: 19683298
[TBL] [Abstract][Full Text] [Related]
9. Editorial comment on: neurogenic detrusor overactivity treated with english botulinum toxin a: 8-year experience of one single centre.
Wyndaele JJ
Eur Urol; 2008 May; 53(5):1019-20. PubMed ID: 17950988
[No Abstract] [Full Text] [Related]
10. Re: Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity.
Sahai A; Dowson C; Khan MS; Dasgupta P
BJU Int; 2008 Feb; 101(4):515-6; author reply 516-7. PubMed ID: 18234066
[No Abstract] [Full Text] [Related]
11. Prospects and limitations of treatment with botulinum neurotoxin type A for patients with refractory idiopathic detrusor overactivity.
Schmid DM; Roy S; Sulser T; Scheiner D
BJU Int; 2008 Jul; 102 Suppl 1():7-10. PubMed ID: 18665972
[TBL] [Abstract][Full Text] [Related]
12. Health economics and intradetrusor injections of botulinum for the treatment of detrusor overactivity.
Sangster P; Kalsi V
BJU Int; 2008 Jul; 102 Suppl 1():17-9. PubMed ID: 18665974
[TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.
Antunes AA; Srougi M; Coelho RF; de Campos Freire G
Nat Clin Pract Urol; 2007 Mar; 4(3):155-60. PubMed ID: 17347660
[TBL] [Abstract][Full Text] [Related]
14. Patients' perspective of botulinum toxin-A as a long-term treatment option for neurogenic detrusor overactivity secondary to spinal cord injury.
Hori S; Patki P; Attar KH; Ismail S; Vasconcelos JC; Shah PJ
BJU Int; 2009 Jul; 104(2):216-20. PubMed ID: 19220255
[TBL] [Abstract][Full Text] [Related]
15. [Guidelines for treatment of urinary incontinence in women due to refractory idiopathic vesical hyperactivity with botulinum toxin A].
Peyrat L; Ragni E;
Prog Urol; 2010 Feb; 20 Suppl 2():S170-3. PubMed ID: 20403570
[TBL] [Abstract][Full Text] [Related]
16. Short-term efficacy of botulinum toxin a for refractory overactive bladder in the elderly population.
White WM; Pickens RB; Doggweiler R; Klein FA
J Urol; 2008 Dec; 180(6):2522-6. PubMed ID: 18930481
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial.
Sahai A; Khan MS; Dasgupta P
J Urol; 2007 Jun; 177(6):2231-6. PubMed ID: 17509328
[TBL] [Abstract][Full Text] [Related]
18. Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units.
Cohen BL; Barboglio P; Rodriguez D; Gousse AE
Neurourol Urodyn; 2009; 28(3):205-8. PubMed ID: 19058190
[TBL] [Abstract][Full Text] [Related]
19. The current standing of intramural injection of botulinum neurotoxin in managing the overactive bladder.
Drake MJ
BJU Int; 2008 Jul; 102 Suppl 1():1. PubMed ID: 18665970
[No Abstract] [Full Text] [Related]
20. Botulinum A toxin in the treatment of neurogenic detrusor overactivity: a consolidated field of application.
Giannantoni A; Mearini E; Del Zingaro M; Santaniello F; Porena M
BJU Int; 2008 Jul; 102 Suppl 1():2-6. PubMed ID: 18665971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
